Mutations in the IDH enzyme lead to the conversion of αKG into 2HG, the oncometabolite which promotes gliomagenesis while inhibiting anti-tumor immunity.39 As a result, inhibiting mutant IDH activity is being considered as a therapeutic approach. Here, IDH1 is linked to neoplasm.